Targeting CXCL10/CXCR3 signaling inhibited the mobilization of Treg and EPC, attenuated early-phase liver graft injury, and prevented late-phase tumor recurrence/metastasis after transplantation (79, 80). The gene discussed is CXCL10; the disease is neoplasm.